```html

Quinidine‑Induced Heart Block – A Complete Patient Guide

Overview

Quinidine heart block refers to a conduction disturbance of the heart’s electrical system that occurs as a side‑effect of the anti‑arrhythmic drug quinidine. Quinidine belongs to the class Ia anti‑arrhythmics and is used to treat atrial fibrillation, atrial flutter, and certain ventricular arrhythmias. While it can be effective, quinidine can slow or interrupt the flow of electrical impulses through the atrioventricular (AV) node, leading to varying degrees of heart block.

• Who it affects: Adults prescribed quinidine, particularly older patients (≥65 years), those with pre‑existing conduction disease, structural heart disease, or electrolyte abnormalities.
• Prevalence: Drug‑induced heart block is relatively rare. In clinical trials of quinidine, AV block of any grade occurred in 2–5 % of patients, with higher rates in those with baseline conduction delay.
• Geographic variation: Usage of quinidine varies worldwide; in the United States it accounts for <1 % of anti‑arrhythmic prescriptions, whereas some low‑resource settings still use it more frequently because of cost.

Symptoms

Symptoms depend on the severity (first‑, second‑, or third‑degree) and may be subtle or life‑threatening.

First‑Degree AV Block

• Often asymptomatic.
• Mild fatigue or reduced exercise tolerance.

Second‑Degree AV Block

• Mobitz type I (Wenckebach): Irregular heartbeats with occasional “skipped” beats; light‑headedness.
• Mobitz type II: Sudden dropped beats without warning; near‑syncope or fainting.
• Palpitations, shortness of breath on exertion.

Third‑Degree (Complete) AV Block

• Severe dizziness, fainting (syncope) or near‑syncope.
• Chest discomfort or pressure.
• Marked fatigue, especially after minimal activity.
• Shortness of breath, especially when lying flat (orthopnea).
• Sudden cardiac arrest (rare but possible if block is profound).

Causes and Risk Factors

Mechanism

Quinidine blocks sodium channels (class Ia) and also has quinidine‑sensitive potassium‑channel blocking properties. These actions prolong the action potential and the refractory period, particularly in the AV node. In susceptible individuals, this can slow conduction enough to create a block.

Risk Factors

• Pre‑existing conduction disease (e.g., bundle‑branch block, first‑degree AV block).
• Recent myocardial infarction or ischemic heart disease.
• Electrolyte disturbances – especially low potassium (hypokalemia) or magnesium (hypomagnesemia).
• Renal or hepatic impairment → higher quinidine levels.
• Concomitant use of other AV‑node‑slowing drugs (e.g., beta‑blockers, calcium‑channel blockers, digoxin).
• Advanced age and frailty.
• Genetic polymorphisms affecting quinidine metabolism (CYP2D6 poor metabolizers).

Diagnosis

Diagnosis relies on a combination of clinical history, medication review, and objective testing.

Step‑by‑Step Approach

1. Medication reconciliation: Confirm current quinidine dose, formulation (sustained‑release vs. immediate‑release), and recent dosage changes.
2. Physical examination: Look for bradycardia, irregular pulse, signs of heart failure.
3. 12‑lead Electrocardiogram (ECG): The cornerstone test.
   • First‑degree block: PR interval >200 ms.
   • Second‑degree block: Dropped QRS complexes, pattern distinguishes Wenckebach vs. Mobitz II.
   • Third‑degree block: Complete dissociation of P‑waves and QRS complexes.
4. Holter monitor (24‑48 h) or event recorder: Detect intermittent block that might be missed on a single ECG.
5. Laboratory tests: Serum electrolytes, renal and hepatic function, quinidine plasma level (if available).
6. Echocardiogram (optional): Assess ventricular function and rule out structural heart disease that may exacerbate block.

Treatment Options

Treatment aims to stop or reverse the drug‑induced block while managing the underlying arrhythmia.

Immediate Measures

• Discontinue quinidine: The most effective first step. In many cases, AV conduction improves within 24–48 hours after stopping the drug.
• Temporary pacing: If the patient is hemodynamically unstable (syncope, severe bradycardia <40 bpm), a transvenous or external pacing system may be required.

Alternative Anti‑arrhythmic Strategies

• Class III agents (e.g., amiodarone, sotalol): Often used when quinidine is not tolerated; they have a different impact on AV nodal conduction.
• Rate‑control drugs: Beta‑blockers or non‑dihydropyridine calcium‑channel blockers can be considered if the original indication was atrial fibrillation and strict rhythm control is not essential.
• Catheter ablation: Definitive treatment for atrial fibrillation/flutter that eliminates the need for anti‑arrhythmic drugs.

Long‑Term Management

• Permanent pacemaker: Indicated if high‑grade AV block persists >48 h after quinidine cessation, or if the patient has symptomatic bradycardia despite drug withdrawal.
• Electrolyte optimization: Maintain K⁺ > 4.0 mmol/L and Mg²⁺ > 2.0 mg/dL.
• Monitoring: Repeat ECG 1–2 weeks after stopping quinidine; then at 3‑month intervals if any conduction abnormality lingers.

Living with Quinidine Heart Block

Daily Management Tips

• Medication list: Keep an up‑to‑date list of all prescribed, over‑the‑counter, and herbal products; share it with every clinician.
• Regular ECG checks: Even if you feel fine, an annual ECG is advisable for patients with a prior block.
• Stay hydrated and maintain electrolytes: Especially important if you are on diuretics.
• Avoid sudden posture changes: Rise slowly from sitting or lying to prevent dizziness.
• Exercise wisely: Low‑to‑moderate intensity aerobic activity is safe; high‑intensity bursts may trigger arrhythmias—consult your cardiologist.
• Travel precautions: Carry a copy of your ECG and a list of emergency contacts; if you have a pacemaker, bring the magnet‑safety card.
• Watch for medication interactions: Drugs such as macrolide antibiotics, antifungals, and certain antidepressants can raise quinidine levels.

Prevention

While some cases are idiosyncratic, many can be prevented with vigilant care.

• Risk‑stratify before prescribing: Obtain a baseline ECG; avoid quinidine if PR interval >200 ms.
• Start low, go slow: Use the lowest effective quinidine dose and titrate cautiously.
• Correct electrolytes before and during therapy.
• Monitor drug levels (where available) in patients with renal/hepatic dysfunction.
• Educate patients: Explain signs of bradycardia and when to call a doctor.
• Consider alternatives early: For patients with known conduction disease, favor non‑AV‑node‑blocking therapies.

Complications

If quinidine‑induced block is not recognized or treated promptly, several serious outcomes can arise.

• Syncope and falls: Leading cause of injury, especially in older adults.
• Heart failure: Persistent bradycardia reduces cardiac output.
• Sudden cardiac death: Rare but possible with high‑grade block and ventricular arrhythmias.
• Pacemaker‑related complications: Infection, lead dislodgement, or device malfunction in those who ultimately require implantation.

When to Seek Emergency Care

References

• Mayo Clinic. “Quinidine (Oral Route).” mayoclinic.org.
• American Heart Association. “Heart Block.” heart.org.
• National Institutes of Health, National Library of Medicine. “Drug‑Induced Cardiac Conduction Disorders.” pubmed.ncbi.nlm.nih.gov.
• Cleveland Clinic. “AV Block – Types, Symptoms, Treatment.” clevelandclinic.org.
• World Health Organization. “WHO Essential Medicines List (2023).” who.int.

```